PSP Investments Leads Series B Round in Valo Health
Posted on 01/11/2021
Boston-based Valo Health LLC (Valo), a technology company working to transform the drug discovery and development process and accelerate the creation of life-changing drugs, closed a US$ 190 million Series B financing and unveiled select therapeutic programs. This is preferred equity capital. In total, Valo Health has raised over US$ 285 million. The financing was led by The Public Sector Pension Investment Board (PSP Investments). Joining the Series B financing are all of Valo’s existing major investors including Flagship Pioneering and several new institutional investors including Invus Public Equities, HBM Healthcare Investments, Atinum Investment, and Mirae Asset Capital. The proceeds from the Series B will support the continued discovery and development of therapeutic programs and will further build-out of the Company’s proprietary Opal Computational Platform, working capital, and other general purposes.
